Browse News
Filter News
Found 171 articles
-
This is the latest rundown of people coming and going from executive positions at biopharma companies that BioSpace covers. This regular column highlights the hired, fired, retired, promoted or resigning, as well as those personally named in lawsuits.
-
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
3/12/2024
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the fourth quarter of 2023 and year-ended 2023.
-
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
3/6/2024
Corbus Pharmaceuticals Holdings, Inc. today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion at BMO Capital Markets Inaugural BMO Obesity Summit to be held on March 20, 2024 in New York City, NY.
-
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
2/28/2024
Corbus Pharmaceuticals Holdings, Inc., a precision oncology company with a diversified portfolio, announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company’s Chief Medical Officer.
-
Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2/6/2024
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024.
-
Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
2/2/2024
Corbus Pharmaceuticals Holdings, Inc. announced the closing of its public offering of 4,973,750 shares of its common stock, including 648,750 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.
-
Corbus Pharmaceuticals Announces Pricing of Public Offering
1/31/2024
Corbus Pharmaceuticals Holdings, Inc. today announced the pricing of an underwritten public offering of 4,325,000 shares of its common stock at a public offering price of $19.00 per share.
-
Corbus Pharmaceuticals Announces Proposed Public Offering - Jan 30, 2024
1/30/2024
Corbus Pharmaceuticals Holdings, Inc., a precision oncology company with a diversified portfolio, announced that it plans to offer and sell shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock in an underwritten registered public offering.
-
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024
1/26/2024
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that data from the first-in-human clinical study of CRB-701 (SYS6002) is being presented as a poster by the Company’s development partner CSPC Pharmaceutical Group at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).
-
Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU
1/23/2024
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), announced today that the abstract for the first-in-human Phase 1 dose escalation study of SYS6002 (CRB-701) has been released, and the corresponding up-to-date data will be presented at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).
-
Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)
1/9/2024
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application of CRB-601, a potentially best-in-class TGFβ blocking monoclonal antibody targeting the integrin αvβ8.
-
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU
12/18/2023
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced that the Phase 1, first-in-human clinical data from a dose escalation study being carried out by its partner CSPC in China with CRB-701 (SYS6002) has been accepted for presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).
-
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/7/2023
Corbus Pharmaceuticals Holdings, Inc. today provided a corporate update and reported financial results for the third quarter of 2023.
-
Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting
11/2/2023
Corbus Pharmaceuticals Holdings, Inc. announced that results from two pre-clinical studies on its CRB-601 anti-aVb8 integrin monoclonal antibody were presented as posters at the 38th Annual Meeting of the Society for Immunotherapy of Cancer, being held in San Diego, CA November 1-5, 2023.
-
Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023
10/17/2023
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced results of a pre-clinical study on its CRB-913 cannabinoid type-1 receptor (CB1) inverse agonist have been selected for oral presentation at the 11th annual Obesity Journal Symposium, held during the 2023 Obesity Week Conference in Dallas, Texas October 14-17, 2023.
-
Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701
10/16/2023
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today announced that a poster characterizing the pre-clinical validation of CRB-701, a next generation antibody drug conjugate (ADC) targeting nectin-4 was presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in Boston on October 14th 2023.
-
Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023
10/3/2023
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that it will host a Virtual ‘Meet the Expert’ event on the development of a next generation Nectin-4 antibody drug conjugate, focusing on opportunities and challenges for CRB-701, on Tuesday, October 10, 2023 at 10:30am ET.
-
Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting
9/27/2023
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company") today announced that an abstract highlighting pre-clinical data on its CRB-601 anti-aVb8 integrin monoclonal antibody has been accepted for presentation as a poster at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), to be in San Diego, CA November 1-5, 2023.
-
Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9/19/2023
Corbus Pharmaceuticals Holdings, Inc. today announced the pre-clinical data on its CRB-701 Nectin-4 anti-drug-conjugate (ADC) will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
-
Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8/8/2023
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today provided a corporate update and reported financial results for the second quarter of 2023.